Clinical Trial Update: Apixaban for the Prevention of Latent Biological Valve Thrombosis [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating apixaban for preventing latent bioprosthetic valve thrombosis in patients with aortic valve replacement.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Valve Replacement
• Bioprosthetic Valve Thrombosis

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: Clinical Hospital Centre Zagreb | Conditions: Aortic Valve Replacement, Antithrombotic Therapy | Phase 4 | Status: UNKNOWN